BACKGROUND: Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is being increasingly used in the sampling of pulmonary masses and mediastinal lymphadenopathy. The blood clot core (BCC) often obtained during EBUS-TBNA may not be a true core and therefore may not be submitted for histological analysis. The frequency in which the blood clot core is positive in patients with negative cytology undergoing EBUS-TBNA is not known. The purpose of this study was to evaluate the diagnostic role of the blood clot core obtained during EBUS-TBNA. METHODS: An Institutional Review Board-approved retrospective chart review was performed from January through September 2011 for all patients who underwent EBUS-TBNA at The Ohio State University. The data collection included cytology and histology results for each procedure. Blood clot cores obtained from the EBUS-TBNA needle were sent in formalin for histological examination. RESULTS: Seventy patients underwent EBUS-TBNA and 51 (72.8 %) patients had procedures that yielded a BCC for histology and aspirate for cytology. Forty-nine percent of patients with a BCC were diagnosed with malignancy. Of those with a BCC obtained, five (9.8 %) patients diagnosed with malignancy were done so based only on the results of blood clot core alone with negative cytology. CONCLUSIONS: Blood clot cores obtained at EBUS-TBNA contain diagnostic material and should be subjected histopathological examination. When blood clot cores are sent for analysis, there is the potential to spare up to 10 % of patients more invasive diagnostic biopsy procedures.
BACKGROUND: Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is being increasingly used in the sampling of pulmonary masses and mediastinal lymphadenopathy. The blood clot core (BCC) often obtained during EBUS-TBNA may not be a true core and therefore may not be submitted for histological analysis. The frequency in which the blood clot core is positive in patients with negative cytology undergoing EBUS-TBNA is not known. The purpose of this study was to evaluate the diagnostic role of the blood clot core obtained during EBUS-TBNA. METHODS: An Institutional Review Board-approved retrospective chart review was performed from January through September 2011 for all patients who underwent EBUS-TBNA at The Ohio State University. The data collection included cytology and histology results for each procedure. Blood clot cores obtained from the EBUS-TBNA needle were sent in formalin for histological examination. RESULTS: Seventy patients underwent EBUS-TBNA and 51 (72.8 %) patients had procedures that yielded a BCC for histology and aspirate for cytology. Forty-nine percent of patients with a BCC were diagnosed with malignancy. Of those with a BCC obtained, five (9.8 %) patients diagnosed with malignancy were done so based only on the results of blood clot core alone with negative cytology. CONCLUSIONS: Blood clot cores obtained at EBUS-TBNA contain diagnostic material and should be subjected histopathological examination. When blood clot cores are sent for analysis, there is the potential to spare up to 10 % of patients more invasive diagnostic biopsy procedures.
Authors: Rex Chin Wei Yung; Susan Otell; Peter Illei; Douglas P Clark; David Feller-Kopman; Lonny Yarmus; Frederic Askin; Edward Gabrielson; Qing Kay Li Journal: Cancer Cytopathol Date: 2011-12-05 Impact factor: 5.284
Authors: Kazuhiro Yasufuku; Andrew Pierre; Gail Darling; Marc de Perrot; Thomas Waddell; Michael Johnston; Gilda da Cunha Santos; William Geddie; Scott Boerner; Lisa W Le; Shaf Keshavjee Journal: J Thorac Cardiovasc Surg Date: 2011-10-02 Impact factor: 5.209
Authors: Michael B Wallace; Jorge M S Pascual; Massimo Raimondo; Timothy A Woodward; Barbara L McComb; Julia E Crook; Margaret M Johnson; Mohammad A Al-Haddad; Seth A Gross; Surakit Pungpapong; Joy N Hardee; John A Odell Journal: JAMA Date: 2008-02-06 Impact factor: 56.272
Authors: Jinkyeong Park; Se Jin Jang; Young Soo Park; Yeon-Mok Oh; Tae Sun Shim; Woo Sung Kim; Chang Min Choi Journal: J Korean Med Sci Date: 2011-01-24 Impact factor: 2.153
Authors: Elliot B Levy; Maria I Fiel; Stanley R Hamilton; David E Kleiner; Shannon J McCall; Peter Schirmacher; William Travis; Michael D Kuo; Robert D Suh; Alda L Tam; Shaheen U Islam; Katherine Ferry-Galow; Rebecca A Enos; James H Doroshow; Hala R Makhlouf Journal: J Clin Oncol Date: 2020-03-05 Impact factor: 44.544